Advertisement Fresenius Kabi launches Kabiven in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Fresenius Kabi launches Kabiven in US

Fresenius Kabi has launched Kabiven (amino acids, electrolytes, dextrose and lipid injectable emulsion) for intravenous use, with immediate availability. Kabiven is a parenteral nutrition (PN) product in a three-chamber bag – the only container of its kind approved in the US.

Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition.

Kabiven was approved by the U.S. Food and Drug Administration in August. It is an intravenously infused solution of lipids, dextrose, amino acids and electrolytes in a three-chamber bag that efficiently delivers these nutrients in volumes and concentrations that meet the nutritional needs of most patients.

Fresenius Kabi expects to introduce Perikabiven® in November. Perikabiven is another Fresenius Kabi PN product that was also approved by the FDA in August. Perikabiven is intended for peripheral intravenous administration. Outside the United States, Kabiven is sold in more than 85 countries and has been used to treat millions of patients since its initial marketing authorization in 1999.

Kabiven and Perikabiven three-chamber bags contain amino acids with electrolytes, dextrose and lipids (Intralipid® 20%). The design of the three-chamber bag keeps the macronutrients separate and shelf-stable (without refrigeration) until the bag is activated and the contents mixed together for patient use. The formula is intended to meet the daily nutritional requirements of broad patient populations.